A phase II study of CPX-351 in adult patients with first-relapse acute myeloid leukemia demonstrated clinical benefit in patients with poor-risk disease as defined by the European Prognostic Index.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe